T Cell Clinical Trials

183 recruitingLast updated: June 17, 2026

There are 183 actively recruiting t cell clinical trials across 35 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Shanghai, Shanghai Municipality, China, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


T Cell Trials at a Glance

183 actively recruiting trials for t cell are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Phase 2 with 60 trials, with the heaviest enrollment activity in New York, Shanghai, and Guangzhou. Lead sponsors running t cell studies include Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Institute of Hematology & Blood Diseases Hospital, China, and Sun Yat-sen University.

Treatments under study

About T Cell Clinical Trials

Looking for clinical trials for T Cell? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new T Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about T Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 183 trials

Recruiting
Phase 2

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

Tenosynovial Giant Cell Tumor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany20 enrolled3 locationsNCT07499362
Recruiting

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

ANCA-associated VasculitisGiant Cell ArteritisTakayasu's Arteritis+2 more
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)4,000 enrolled1 locationNCT02257866
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting
Phase 1Phase 2

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

CAR-T CellSLESystemic Lupus Erythematosus (SLE)+4 more
Children's Hospital of Philadelphia24 enrolled1 locationNCT06839976
Recruiting
Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 4

Pediatric Long-Term Follow-up and Rollover Study

Neurofibromatosis Type 1GlioblastomaAnaplastic Astrocytoma+20 more
Novartis Pharmaceuticals165 enrolled55 locationsNCT03975829
Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL)Hairy Cell Leukemia (HCL)Non-Hodgkins Lymphoma (NHL)+2 more
National Cancer Institute (NCI)1,263 enrolled1 locationNCT01087333
Recruiting
Phase 3

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Peripheral T Cell Lymphoma
Dizal Pharmaceuticals218 enrolled51 locationsNCT07234162
Recruiting
Phase 2

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Giant Cell Arteritis (GCA)
National Institute of Allergy and Infectious Diseases (NIAID)78 enrolled7 locationsNCT07108387
Recruiting
Early Phase 1

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

LymphomaLeukemiaCAR-T Cell Therapy+3 more
University of Arizona200 enrolled1 locationNCT06643221
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Diffuse Large B Cell LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma+16 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Early Phase 1

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

CAR-T Cell Therapy
RenJi Hospital18 enrolled1 locationNCT05858684
Recruiting
Phase 2

Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection

HTLV-1 InfectionNeuritisHTLV I Associated Myelopathies+1 more
Carlos Brites146 enrolled1 locationNCT07555431
Recruiting
Phase 2

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

Colorectal, CancerLynch SyndromeT Cells
M.D. Anderson Cancer Center40 enrolled1 locationNCT05411718
Recruiting

Disease Activity Monitoring in Patients With Giant Cell Arteritis Study

Giant Cell Arteritis (GCA)
University of Aarhus175 enrolled7 locationsNCT07552636
Recruiting
Phase 1

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting

TRACP-5b for Diagnosis and Follow-up of Giant Cell Tumor of Bone

Giant Cell Tumor of BoneTRACP-5bDisease Surveillance and Monitoring+1 more
St. Anne's University Hospital Brno, Czech Republic70 enrolled1 locationNCT07609277
Recruiting

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Clonal Mast Cell DiseaseKIT D816V MutationSuspected KITD816V Mutated Clonal Mast Cell Disease
Blueprint Medicines Corporation450 enrolled18 locationsNCT07143669
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Not Applicable

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

LeukemiaAcute Myeloid Leukemia in RemissionLymphoblastic Lymphoma+10 more
Medical College of Wisconsin40 enrolled1 locationNCT05794880